vTv Therapeutics Inc. (VTVT)
VTVT Stock Price Chart
Explore vTv Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze VTVT price movements and trends.
VTVT Company Profile
Discover essential business fundamentals and corporate details for vTv Therapeutics Inc. (VTVT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jul 2015
Employees
23.00
Website
https://www.vtvtherapeutics.comCEO
Paul J. Sekhri
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
VTVT Financial Timeline
Browse a chronological timeline of vTv Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.97.
Earnings released on 12 Aug 2025
EPS came in at -$0.92 falling short of the estimated -$0.85 by -8.24%.
Earnings released on 15 May 2025
EPS came in at -$0.77 falling short of the estimated -$0.73 by -5.48%.
Earnings released on 20 Mar 2025
EPS came in at -$0.55 surpassing the estimated -$0.87 by +36.78%, while revenue for the quarter reached $17.00K .
Earnings released on 12 Nov 2024
EPS came in at -$0.88 surpassing the estimated -$3.60 by +75.56%.
Earnings released on 8 Aug 2024
EPS came in at -$0.81 surpassing the estimated -$3.20 by +74.69%.
Earnings released on 9 May 2024
EPS came in at -$1.17 surpassing the estimated -$3.20 by +63.44%, while revenue for the quarter reached $1.00M .
Earnings released on 13 Mar 2024
EPS came in at -$1.67 surpassing the estimated -$2.80 by +40.36%, while revenue for the quarter reached -$9.00K .
Stock split effective on 21 Nov 2023
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$3.20 matching the estimated -$3.20.
Earnings released on 11 Aug 2023
EPS came in at -$2.80 falling short of the estimated -$0.07 by -3.90K%, while revenue for the quarter reached $9.00K .
Earnings released on 11 May 2023
EPS came in at -$2.40 surpassing the estimated -$3.20 by +25.00%.
Earnings released on 6 Mar 2023
EPS came in at -$2.40 matching the estimated -$2.40, while revenue for the quarter reached $9.00K .
Earnings released on 10 Nov 2022
EPS came in at -$2.00 matching the estimated -$2.00.
Earnings released on 15 Aug 2022
EPS came in at -$1.60 surpassing the estimated -$4.00 by +60.00%, while revenue for the quarter reached $9.00K .
Earnings released on 12 May 2022
EPS came in at -$4.00 falling short of the estimated -$3.20 by -25.00%, while revenue for the quarter reached $2.00M .
Earnings released on 29 Mar 2022
EPS came in at -$3.20 matching the estimated -$3.20, while revenue for the quarter reached $9.00K , missing expectations by -98.20%.
Earnings released on 9 Nov 2021
EPS came in at -$0.80 surpassing the estimated -$2.80 by +71.43%, while revenue for the quarter reached $3.00M , beating expectations by +130.77%.
Earnings released on 4 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$2.80 by +85.71%, while revenue for the quarter reached $9.00K , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$3.60 falling short of the estimated -$2.40 by -50.00%, while revenue for the quarter reached $987.00K , beating expectations by +23.38%.
Earnings released on 24 Feb 2021
EPS came in at $0.80 surpassing the estimated -$2.40 by +133.33%, while revenue for the quarter reached $6.40M , beating expectations by +93.91%.
Earnings released on 5 Nov 2020
EPS came in at -$1.20 surpassing the estimated -$4.40 by +72.73%, while revenue for the quarter reached $7.00K , missing expectations by -66.67%.
VTVT Stock Performance
Access detailed VTVT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.